Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lantern Pharma Inc.LTRN · Entity 7525 | Director · President & CEO | September 19, 2025 | September 23, 2025 |
| Vyant Bio, Inc.CGIX · Entity 116415 | Director · Chief Executive Officer | February 22, 2017 | February 24, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lantern Pharma Inc.
Report date September 19, 2025 · Filed September 23, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2030-06-14 | Direct | 0 |
Reported balance
After 2020-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-15 · Disposition to issuer · Disposed 76,628 · Balance 0 F1: The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and one-third of the option vested 180 days from the grant date with the remaining two-thirds of the option vesting in equal monthly increments over the period commencing the 181st day after the grant date and ending 30 months thereafter (or 36 months after the grant date). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.04 · Expires 2030-06-14 | Direct | 76,628 |
Reported balance
After 2020-06-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-06-15 · Grant · Acquired 76,628 · Balance 76,628 F1: The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and one-third of the option vested 180 days from the grant date with the remaining two-thirds of the option vesting in equal monthly increments over the period commencing the 181st day after the grant date and ending 30 months thereafter (or 36 months after the grant date). |
Filing footnotes · ownership attribution and instrument terms
F1: The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and one-third of the option vested 180 days from the grant date with the remaining two-thirds of the option vesting in equal monthly increments over the period commencing the 181st day after the grant date and ending 30 months thereafter (or 36 months after the grant date).
Vyant Bio, Inc.
Report date February 22, 2017 · Filed February 24, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.50 · Expires 2027-02-22 | Direct | 200,000 |
Reported balance
After 2017-02-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-02-22 · Grant · Acquired 200,000 · Balance 200,000 F1: The shares underlying the option shall vest in 48 equal monthly installments commencing on the date of grant until fully vested, provided that the reporting person remains a service provider to Cancer Genetics, Inc. through each applicable vesting period. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the option shall vest in 48 equal monthly installments commencing on the date of grant until fully vested, provided that the reporting person remains a service provider to Cancer Genetics, Inc. through each applicable vesting period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2024 Filed Jul 17, 2024 16:30 UTC | Lantern Pharma Inc. LTRN · Entity 7525 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $4.35 | $0.00 |
DisclosureSEC source: 0001493152-24-028187 · ownership.xml · derivative · entry 1 SHARMA PANNA · CIK 0001157989 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2034-07-15 F1 · derivative.exercise_date: The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options will vest and first become exercisable in equal monthly increments over a 24-month period commencing August 15, 2024. Read SEC document |
| August 06, 2022 Filed Aug 9, 2022 16:26 UTC | Lantern Pharma Inc. LTRN · Entity 7525 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $5.60 | $0.00 |
DisclosureSEC source: 0001213900-22-045909 · ownership.xml · derivative · entry 1 SHARMA PANNA · CIK 0001157989 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-08-06 F1 · derivative.exercise_date: The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options will vest and first become exercisable in equal monthly increments over a 36-month period commencing September 8, 2022, with the vesting of the options to accelerate in the event the closing price for our common stock is at least $15.00 per share. Read SEC document |
| June 15, 2020 Filed Jun 15, 2020 17:34 UTC | Lantern Pharma Inc. LTRN · Entity 7525 | GrantStock Option · Derivative | 76,628 | Not disclosed Strike: $15.00 | Not disclosed |
DisclosureSEC source: 0001213900-20-015051 · ownership.xml · derivative · entry 1 SHARMA PANNA · CIK 0001157989 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,628 Underlying: Common Stock · 76,628 shares Expires not disclosed F1 · derivative.exercise_price: Pursuant to an amendment to the Reporting Person's employment agreement, the Reporting Person was granted stock options to purchase 76,628 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering ("IPO") at an exercise price per share equal to the price per share sold in the Issuer's IPO. One third of the options will vest 180 days after the closing of the Issuer's IPO (the "Grant Date"), with the remaining two thirds of the options vesting in equal monthly increments over a thirty (30) month period commencing the 181st day after the Grant Date. All other terms and conditions of the option grant will be consistent with the terms and conditions permitted under the Issuer's Amended and Restated 2018 Equity Incentive Plan. Under the Amended and Restated 2018 Equity Incentive Plan, the options may not be exercised after the tenth anniversary of the Grant Date. F1 · price: Pursuant to an amendment to the Reporting Person's employment agreement, the Reporting Person was granted stock options to purchase 76,628 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering ("IPO") at an exercise price per share equal to the price per share sold in the Issuer's IPO. One third of the options will vest 180 days after the closing of the Issuer's IPO (the "Grant Date"), with the remaining two thirds of the options vesting in equal monthly increments over a thirty (30) month period commencing the 181st day after the Grant Date. All other terms and conditions of the option grant will be consistent with the terms and conditions permitted under the Issuer's Amended and Restated 2018 Equity Incentive Plan. Under the Amended and Restated 2018 Equity Incentive Plan, the options may not be exercised after the tenth anniversary of the Grant Date. F1 · derivative.exercise_date: Pursuant to an amendment to the Reporting Person's employment agreement, the Reporting Person was granted stock options to purchase 76,628 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering ("IPO") at an exercise price per share equal to the price per share sold in the Issuer's IPO. One third of the options will vest 180 days after the closing of the Issuer's IPO (the "Grant Date"), with the remaining two thirds of the options vesting in equal monthly increments over a thirty (30) month period commencing the 181st day after the Grant Date. All other terms and conditions of the option grant will be consistent with the terms and conditions permitted under the Issuer's Amended and Restated 2018 Equity Incentive Plan. Under the Amended and Restated 2018 Equity Incentive Plan, the options may not be exercised after the tenth anniversary of the Grant Date. F1 · derivative.expiration_date: Pursuant to an amendment to the Reporting Person's employment agreement, the Reporting Person was granted stock options to purchase 76,628 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering ("IPO") at an exercise price per share equal to the price per share sold in the Issuer's IPO. One third of the options will vest 180 days after the closing of the Issuer's IPO (the "Grant Date"), with the remaining two thirds of the options vesting in equal monthly increments over a thirty (30) month period commencing the 181st day after the Grant Date. All other terms and conditions of the option grant will be consistent with the terms and conditions permitted under the Issuer's Amended and Restated 2018 Equity Incentive Plan. Under the Amended and Restated 2018 Equity Incentive Plan, the options may not be exercised after the tenth anniversary of the Grant Date. Read SEC document |
| June 15, 2020 Filed Sep 23, 2025 16:05 UTC | Lantern Pharma Inc. LTRN · Entity 7525 | GrantStock Option (Right to Buy) · Derivative | 76,628 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001493152-25-014616 · ownership.xml · derivative · entry 2 SHARMA PANNA · CIK 0001157989 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,628 Underlying: Common Stock · 76,628 shares Expires 2030-06-14 F1 · kind: The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and one-third of the option vested 180 days from the grant date with the remaining two-thirds of the option vesting in equal monthly increments over the period commencing the 181st day after the grant date and ending 30 months thereafter (or 36 months after the grant date). F1 · derivative.exercise_date: The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and one-third of the option vested 180 days from the grant date with the remaining two-thirds of the option vesting in equal monthly increments over the period commencing the 181st day after the grant date and ending 30 months thereafter (or 36 months after the grant date). Read SEC document |
| June 15, 2020 Filed Sep 23, 2025 16:05 UTC | Lantern Pharma Inc. LTRN · Entity 7525 | Disposition to issuerStock Option (Right to Buy) · Derivative | 76,628 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001493152-25-014616 · ownership.xml · derivative · entry 1 SHARMA PANNA · CIK 0001157989 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 76,628 shares Expires 2030-06-14 F1 · kind: The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and one-third of the option vested 180 days from the grant date with the remaining two-thirds of the option vesting in equal monthly increments over the period commencing the 181st day after the grant date and ending 30 months thereafter (or 36 months after the grant date). F1 · derivative.exercise_date: The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and one-third of the option vested 180 days from the grant date with the remaining two-thirds of the option vesting in equal monthly increments over the period commencing the 181st day after the grant date and ending 30 months thereafter (or 36 months after the grant date). Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 17:00 UTC | Vyant Bio, Inc. CGIX · Entity 116415 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001349929-17-000019 · wf-form4_148797360556721.xml · derivative · entry 1 SHARMA PANNA · CIK 0001157989 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock, par value $0.0001 per share · 200,000 shares Expires 2027-02-22 F1 · derivative.exercise_date: The shares underlying the option shall vest in 48 equal monthly installments commencing on the date of grant until fully vested, provided that the reporting person remains a service provider to Cancer Genetics, Inc. through each applicable vesting period. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.